Journal Article

DKFZ-2025-02366

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Targeted therapy in patients with genetic tumor syndromes.

Jahn, A.DKFZ* ; Heining, C.DKFZ* ; Fröhling, S.DKFZ* ; Glimm, H.DKFZ* ; Schröck, E.DKFZ*

2025
de Gruyter Berlin

Abstract: Significant progress in comprehensive molecular diagnostics and targeted therapies for advanced malignancies has, in part, led to substantial improvements in patient outcomes. Nevertheless, comprehensive genomic profiling necessitates interdisciplinary discussion of potential clinical recommendations within interdisciplinary molecular tumor boards. (Likely) pathogenic germline variants (PGVs) typically warrant genetic counseling for patients and, where appropriate, their relatives. Concurrently, the rapidly expanding availability of targeted therapies introduces new therapeutic implications based on germline alterations that must be integrated into clinical decision-making. Moreover, the identification of PGVs may not only inform therapy in patients with manifest malignancy but also offer opportunities for targeted chemoprevention.

Keyword(s): Precision oncology ; biomarker-targeted therapy ; clinical trials ; genetic testing and prevention ; genetic tumor syndrome

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Dresden (DD01)
2. Translationale Medizinische Onkologie (B340)
3. DKTK HD zentral (HD01)
4. B280 Translationale funktionelle Krebsgenomik (B280)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2025

---

Database coverage:
; ; Clarivate Analytics Master Journal List ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---